Edesa Biotech IncEDSA
Price$4.01

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$14.1MTTM through 30 Jun 2026
Free Cash Flow -$8.9MTTM through 30 Jun 2026

Margins

Current

Returns

-57.8%ROE
-53.1%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio10.67x
Net Debt-$10.8Mnet cash position
Cash & Equivalents$10.3M

Quality Metrics

Altman Z-Score-5.70
Piotroski F-Score1 / 9
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'14'15'16'17'18'20'21
FY2021: $0
Diluted EPS
'13'14'15'16'23'24'25
FY2025: $-1.27

Dividend

No dividend

Capital Allocation

R&D Spend$9.1M

Segment Performance

SegmentRevenueYoYOutlook
Biopharmaceutical Development$0
View details

Phase 2 clinical trial of EB06 in vitiligo patients is expected to initiate in mid-2026.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.